Reinventing Medicine

with Protein Degradation

Our Company

Expanding the Range of
Treatable Disease

Kymera is committed to advancing cutting-edge science to develop a new generation of medicines that address critical health problems and dramatically improve patients’ lives by targeting the fundamental drivers of disease.

Redefining New Treatment Paradigms

Targeted protein degradation is a disease-agnostic modality fundamentally changing how drugs can work, creating unprecedented opportunities to treat a wide variety of diseases.

Our Company

Our team is committed to delivering life-changing medicines with passion, focus, and a sense of urgency.

Our Pipeline

Driven by our powerful and highly productive drug discovery engine, we are delivering a pipeline of first-in-class therapeutics designed to transform the standard of care for patients.

Recent News
June 14, 2024
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 1, 2024
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
May 29, 2024
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
Our Team

Kymera is building a fully integrated medicines company to redefine disease treatment. Learn more about how you can help shape the future of medicine.